Teknova Q2 revenue $12.2M (+18% YoY); raises FY 2026 guidance to $45-47M

Alpha Teknova, Inc.

Q2 2026 revenue $12.2M, up 18% from $10.3M in Q2 2025; net loss narrowed to $3.2M ($0.06 loss per share).
Lab Essentials revenue $9.2M (+18% YoY); Clinical Solutions $2.4M (+18% YoY).
Gross margin improved to 40.1% from 38.7%; Free Cash Outflow reduced to $0.6M from $2.3M.
FY 2026 revenue guidance raised to $45-47M; Free Cash Outflow expected <$8M.
Launched AI-powered Build-Tek custom order configurator for faster preclinical-to-clinical manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.